Production (Stage)
Interpace Biosciences, Inc.
IDXG
$0.80
$0.022.56%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.14% | 21.88% | 35.44% | 9.21% | 3.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.14% | 21.88% | 35.44% | 9.21% | 3.58% |
| Cost of Revenue | 7.19% | 20.66% | 16.13% | 10.02% | 0.49% |
| Gross Profit | 16.78% | 22.35% | 51.51% | 8.72% | 5.57% |
| SG&A Expenses | 6.01% | 21.89% | 16.88% | -8.57% | 4.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.86% | 21.11% | 14.25% | -4.01% | -0.95% |
| Operating Income | 64.18% | 24.27% | 12,006.25% | 171.27% | 65.04% |
| Income Before Tax | 117.16% | 45.44% | 360.69% | 436.34% | 88.02% |
| Income Tax Expenses | 350.00% | -260.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | 116.01% | 46.21% | 357.95% | 440.76% | 88.84% |
| Earnings from Discontinued Operations | -2.88% | -78.67% | 4.65% | 66.36% | -31.65% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 132.63% | 41.63% | 308.47% | 1,078.29% | 101.71% |
| EBIT | 64.18% | 24.27% | 12,006.25% | 171.27% | 65.04% |
| EBITDA | 65.01% | 24.49% | 788.84% | 95.29% | 13.09% |
| EPS Basic | 130.00% | 16.84% | 304.92% | 1,060.59% | 98.77% |
| Normalized Basic EPS | 114.74% | 42.42% | 356.33% | 428.72% | 85.24% |
| EPS Diluted | -65.37% | -89.66% | 304.99% | 1,108.21% | 98.77% |
| Normalized Diluted EPS | -65.61% | -87.37% | 354.62% | 425.78% | 84.60% |
| Average Basic Shares Outstanding | 1.14% | 1.75% | 1.71% | 1.51% | 1.46% |
| Average Diluted Shares Outstanding | 531.93% | 1,045.71% | 2.41% | 1.97% | 1.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |